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Prediction of quality of life in early breast cancer upon
completion of adjuvant chemotherapy
Alberto Carmona-Bayonas 1✉, Caterina Calderón2, Raquel Hernández3, Ana Fernández Montes4, Beatriz Castelo5,
Laura Ciria-Suarez 6, Mónica Antoñanzas 7, Jacobo Rogado8, Vilma Pacheco-Barcia 9, Elena Asensio Martínez10, Alejandra Ivars1,
Francisco Ayala de la Peña1 and Paula Jimenez-Fonseca11
Quality of life (QoL) is a complex, ordinal endpoint with multiple conditioning factors. A predictive model of QoL after adjuvant
chemotherapy can support decision making or the communication of information about the range of treatment options available.
Patients with localized breast cancer (n= 219) were prospectively recruited at 17 centers. Participants completed the EORTC QLQ-
C30 questionnaire. The primary aim was to predict health status upon completion of adjuvant chemotherapy adjusted for multiple
covariates. We developed a Bayesian model with six covariates (chemotherapy regimen, TNM stage, axillary lymph node dissection,
perceived risk of recurrence, age, type of surgery, and baseline EORTC scores). This model allows both prediction and causal
inference. The patients with mastectomy reported a discrete decline on all QoL scores. The effect of surgery depended on the
interaction with age. Women with ages on either end of the range displayed worse scores, especially with mastectomy. The
perceived risk of recurrence had a striking effect on health status. In conclusion, we have developed a predictive model of health
status in patients with early breast cancer based on the individual’s profile.
npj Breast Cancer            (2021) 7:92 ; https://doi.org/10.1038/s41523-021-00296-8
INTRODUCTION
In recent decades, we have witnessed an upsurge in the use of
patient-reported outcomes (PROs), such as quality of life (QoL),
when designing and interpreting clinical trials. These endpoints,
together with physician-reported outcomes, are beginning to be
taken into account vis-à-vis regulations, as well as therapeutic
decision making1,2. Thus, the European Society of Medical
Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), a
tool that classifies the magnitude of benefit that can be expected
from anticancer treatments, integrates QoL estimations in addition
to efficacy and toxicity variables3.
In women with breast cancer, QoL has numerous interwoven
determinants with mutual, complex, interactions, such as type of
surgery, socio-economic status, psychological factors, age, or
aspects ranging from body image to fear of recurrence4,5. This
multiplicity of factors affecting QoL makes this a complex
endpoint, which often poses an analytical challenge1,6,7. By and
large, simplified analyses with bivariate methods, such as
Wilcoxon signed-rank tests, on the basis of the variables of
interest (e.g., type of surgery) are used to compare QoL. Likewise,
in clinical trials longitudinal models are routinely used that focus
on time to health-related QoL score deterioration, depending on
the study arms8,9.
Such univariate analyses have two fundamental drawbacks: (1)
their inability to make individual predictions on QoL, conditioned
by complex clinical profiles, and (2) the impossibility of pondering
interactions a priori deemed relevant2. Evidence of these
problems is a recent meta-analysis that concluded that modified
radical mastectomy (MRM) results in greater decline on several
QoL domains than breast-conserving surgery (BCS)10. Never-
theless, this methodology is not able to identify the modulating
factors of interest, leaving meaningful questions, such as
interaction with age, up in the air. Thus, when the inference is
made about average subjects, it is not possible to clarify key
aspects, for instance, whether seniors experience the same impact
on their QoL with a mastectomy as much as younger women10.
Overall, these limitations impede conveying information regarding
the spectrum of treatment options, hinders decision making, and
disallows PROs’ support for statements regarding therapeutic
effects7.
One of the reasons for this imprecision in the literature is that
QoL is an ordered categorical variable, which requires the use of
specific ordinal regression methods8,11–13. The most straightfor-
ward is the proportional odds (PO) model14, which assumes that
the effect of each predictor is similar across all levels of the
endpoint14. In the real world, it is easy to find examples in which
this PO assumption is not met, since the relation with the
predictor is not similar for each endpoint category and neighbor-
ing values. This conditions the not-so-trivial need to allow for a
nonhomogenous effect of a subgroup of predictors across QoL
thresholds, treating the variables as nominal, thereby increasing
the random error and complexity of analysis15. As an intermediate
solution, Peterson & Harrell introduced the constrained partial PO
(CPPO) model that assumes a linear, monotonic constriction
for the coefficients of the variables that diverge from the PO
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assumption15,16. CPPO models are an appealing solution to model
QoL based on multiple covariates, by joining accuracy and
parsimony. Despite the above, thus far, this method has been
uncommon in QoL studies12,13,17 or in cohorts of oncological
patients9,18 given the absence of available software. However, the
Coronavirus Disease 2019 (COVID-19) pandemic has prompted the
development of a software program, the R rmsb package, that
enables Bayesian CPPO models to be simply and efficiently
fitted19. The reason is that the evolution of viral diseases, similar to
QoL, is better captured with ordinal endpoints20.
In this situation, the key idea has been to illustrate the
complexity, as well as the opportunities that rich modeling of
QoL poses by means of this family of ordinal models. Thus, the
Bayesian CPPO model is an ideal instrument for both drawing
causal inferences and specifying those covariates that predict QoL.
As proof of concept with respect to the cross-sectional usefulness
of this tool to model these two facets of health status, we have
applied these ideas in patients with breast cancer. The primary aim
of this study was to predict the health status upon completion of
adjuvant chemotherapy adjusted for multiple covariates. Second-
ary objectives comprised to (1) develop an online calculator to
implement this model with potential usefulness for individualized
prediction, integrating R with NET; (2) estimate the effect of the
type of surgery, based on the individual’s age and profile, and (3)
evaluate the incremental benefit of CPPO models versus other
alternatives available in this context.
RESULTS
Patients
The database comprises 339 patients with breast cancer, 219 of
whom were eligible for this analysis, having completed the
questionnaires at baseline and upon completion of adjuvant
treatment. The recruitment process is shown in Supplementary
Fig. 1. The baseline characteristics of the sample are summarized
in Table 1, with no substantial differences between participants
with or without questionnaires after completing adjuvant
chemotherapy (approximately 6 months later). All participants
received adjuvant chemotherapy. Sixty-four percent (64.2%) of the
HER2-positive and 69.3% of the HER2-negative subjects received
postoperative radiotherapy. Supplementary Table 2 displays
baseline characteristics based on type of surgery, BCS (n= 126,
58%), and total mastectomy (n= 93, 42%). In this case, relevant
clinical–pathological differences can be seen, with the total
mastectomy group presenting a more advanced TNM stage (stage
II–III, 78% vs 63%), fewer HER2+ cancers (15% vs 31%), and more
ALND (33% vs 16%) than the BSC group. Other sociodemographic
characteristics were similar across both groups.
The most common occupational status was unemployed,
housewife, temporary worker, or retired in 41% of the cases.
Close to 86% (85.9%) reported that breast cancer had caused
them no or very little economic hardship. The distribution of
health status is shown in Supplementary Fig. 2, prevailing good or
very good scores (e.g., summatory score >50%). Most women
perceive risk of recurrence as high and respond very similarly in
stages I and II (Supplementary Fig. 3A). The perception of risk of
recurrence does not differ on the basis of type of surgery
(Supplementary Fig. 3B).
Effect of surgery on QoL and its domains
Figure 1A and B illustrates box plots with the distribution of scores
depending on type of surgery. At baseline, the physical status
following total mastectomy was only slightly worse compared to
BSC, mean 84.6 vs 88.6, respectively (p= 0.007). In contrast, upon
completion of adjuvant chemotherapy, women who underwent
total mastectomy reported a slight increase in symptoms (e.g.,
mean sum score of 19 vs 24, p= 0.002), as well as significant




at the end of adjuvant
chemotherapy N= 219 (%)
Age (median, range) 52 (26–81) 53 (28–80)
≤35 15 (4.4) 10 (4.5)
36–45 71 (20.9) 42 (19.1)
46–55 124 (36.5) 79 (36.0)
56–65 75 (22.1) 55 (25.1)
66–75 48 (14.1) 29 (13.2)
75–85 6 (1.7) 4 (1.8)
Sex, male 6 (1.7) 2 (0.9)
ECOG Performance status
0 276 (81.4) 165 (75.3)
1 59 (17.4) 50 (22.8)
2 4 (1.2) 4 (1.8)
TNM stage
I 100 (29.5) 66 (30.1)
II 205 (60.5) 130 (59.4)
III 34 (10.0) 23 (10.5)
Menopausal status
Premenopausal 97 (28.6) 67 (30.5)
Perimenopausal 26 (7.6) 16 (7.3)
Postmenopausal 199 (58.7) 131 (59.8)
Unknown 17 (5.0) 5 (2.2)
HER2-positive cancer 81 (24.0) 53 (24.2)
Estrogen-receptor,
positive
213 (62.8) 142 (64.8)
Progesterone-receptor,
positive




196 (57.8) 126 (57.5)
Mastectomy 143 (42.2) 93 (42.5)
Axillary lymph node
dissection
75 (22.1) 52 (23.7)
Adjuvant radiotherapy 226 (66.9) 149 (68%)
Chemotherapy regimen
Taxane-based 222 (65.5) 152 (69.4)




174 (51.3) 115 (52.5)
Employed 142 (41.9) 100 (45.7)
Married/partnered 258 (76.1) 170 (77.6)
Number of children
None 67 (19.8) 41 (18.8)
1 68 (20.1) 40 (18.3)
2 150 (44.1) 102 (46.7)




0 (0-6) 0 (0-5)





141 (41.5) 103 (47.0)
A. Carmona-Bayonas et al.
2













decline on all QoL scores, such as global health status, physical/
role/ emotional functioning, fatigue, and nausea & vomiting (p <
0.05) (Supplementary Table 3). For instance, mean global health
status scores at the end were 62 vs 70 for total mastectomy vs
BCS, respectively (p= 0.004).
Prediction of global health status upon completion of
adjuvant chemotherapy
The frequentist PO model for global health status at 6 months is
illustrated in Supplementary Fig. 4. With this approach, total
mastectomy was associated with worse scores with OR 0.53 (95%
confidence interval, 0.27–1.05). The PO assumption was evaluated
separately for each of its predictors (Supplementary Fig. 5). The PO
holds up well for categorical variables (surgery, perceived risk of
recurrence, ALND, chemotherapy, and stage). However, a devia-
tion is seen with respect to quantitative variables (age, EORTC
QLQ-C30 sum score), critical if we are to comprehend the
individualized effect as a function of them. The multinomial
formulation (complete or partial) generates abstruse, implausible
models (Supplementary Fig. 6).
To allow departures from the PO, a Peterson–Harrell’s CPPO
model was fitted. The coefficients of this more parsimonious
model are displayed in Supplementary Fig. 7. The model has an
acceptable discriminatory ability, c-index 0.65 (95% highest
posterior density interval [HPDI], 0.63–0.67) and a Brier score of
0.21 (95% HPDI 0.19–0.28). Other performance measures are
shown in Supplementary Fig. 8.
The analysis of partial effects on the log odds reveals the
nonlinear influence of age on global health status (worse on both
ends), as well as the risk of worse scores following total
mastectomy or with high perceived risk of recurrence (Fig. 2).
The consequence of assuming constrained parameters in certain
covariates is apparent in the OR plot (Fig. 3). Thus, the magnitude
of association between type of surgery and health status gradually
decreases if the cutoff increases (e.g., OR 0.30, 0.49, and 0.57, for
thresholds of ≥50%, ≥75%, and ≥83%, respectively), denoting a
nonhomogenous effect on the spectrum of this domain. This
trend is similar when comparing young and middle-aged women.
Indeed, the most relevant variables are baseline QoL, extreme age
(young or old), and perceived risk of relapse. In a sensitivity
analysis, the model was fitted including the tumor stage; this
covariate was not associated with QoL, while the other coefficients
remained unaltered (data not shown).
In the frequentist formulation, neither ALND nor locally
advanced stages had a relevant impact after completing adjuvant
chemotherapy (Supplementary Fig. 4). Nevertheless, the Bayesian
approach estimates 78% and 81% of posterior probability of harm,
respectively (Table 2). Likewise, total mastectomy worsened the
health status (cutoff ≥ 83) with OR 0.57 (95% HPDI, 0.28–1.23) and
this translated as a probability of associated harm of 93%, 84%,
and 70% for any magnitude of detriment, effect size >15% and
>30%, respectively. Figure 4 illustrates the model’s ability to
predict health status across four patient profiles, BSC, or total
mastectomy in younger or older women. Finally, we have
designed an online calculator (https://www.prognostictools.es/
neoBreast/inicio.aspx) to make individual predictions. The poster-
ior probability of decline with mastectomy clearly differs based on
age (e.g., the older and younger women suffer greater detriment).
Alternative models (e.g., detailing chemotherapy regimens,
adding anthracyclines or different nonlinear effects, etc.) were
explored but did not fit the data-generating process much better.
DISCUSSION
In this study, we have fit a CPPO model to probe the factors that
predict global health status in women with breast cancer who
undergo surgery and complete systemic adjuvant chemotherapy.
This model was put forth by Peterson & Harrell in 1990 to model
ordinal endpoints, easing the PO assumption, often unmet in
analysis15. These predictions are tricky, since they entail a trade-off
between parsimony and adequate model fit (e.g., the need to
broaden parameters involves increased random error). Among the
compromise solutions, the model used here imposes a linear
constriction on certain selected covariates, which preserves
simplicity15. Despite being deemed a valuable method, the
absence of software has prevented it from being more widely
used12,21. A package recently written to examine ordinal end-
points using this approach in COVID-19 trials affords us an
opportunity for studies on QoL in cancer patients22,23.
As previously reported in the literature, the CPPO model
confirms worse health status following total mastectomy vs BSC10,
although it contributes nuances and additional insights. Firstly,
while total mastectomy increases the probability of QoL scores in
the lowest range, conserving the breast does not increase the
odds of higher scores to the same degree, which must be taken
into account when making predictions. Secondly, age is a
predictive factor per se, albeit it is also a modifier of the effect
of surgery. This interaction is clearly nonlinear, such that both
extremes (younger and older women) fare worse. Nonlinear
effects are adequately captured here using a spline (a function
defined piecewise by polynomials). Thirdly, long-term predictions
require that the starting point be taken into account, which
cannot be done with bivariate methods. The baseline EORTC QLQ-
C30 sum score is therefore germane and, likewise, nonlinear. This
is in line with other data that point toward the existence of
different trajectories in the evolution of QoL, depending on
specific clinical profiles24.
The initial perception of risk of recurrence modulates the
evolution of health status at completion of systemic therapy, in
keeping with other series5,25. Regardless of evaluating partici-
pants’ perception of risk after their appointment with their
oncologist, the correlation with TNM stage is discrete, given that
women measure it similarly when facing stages I and II. The same
holds true for the type of surgery. This indicates that after being
informed, some women perceive a level of risk typically deemed
‘low’ compared to advanced stages or other neoplasms, as being
‘high’. A plausible explanation is that the use of adjuvant
chemotherapy as an eligibility criterion in this study may have





at the end of adjuvant
chemotherapy N= 219 (%)
Unskilled worker 17 (5.0) 10 (4.5)
Semi-skilled worker 5 (1.4) 2 (0.9)
Skilled worker 11 (3.2) 7 (3.2)
Sales 37 (10.9) 26 (11.8)
Administrative-type
employment
32 (9.4) 23 (10.5)
Technical or
professional




3 (0.8) 3 (1.3)
Not available 41 (12.0) 5 (2.2)
Baseline characteristics were measured before the start of adjuvant
chemotherapy
ECOG Eastern Cooperative Oncology Group, TNM tumor-node-metastases,
HER2 human epidermal growth factor receptor 2.
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exceeds their actual probability of relapse. This perception is far
from trivial, as it is projected on health status for at least the
following six months and, therefore, has an identifiable clinical
impact. Nonetheless, the reader must be cognizant of the subtlety
that the woman was asked with respect to her subjective
perception and not about her quantitative prognosis. Be that as
it may, it is not clear that there is a component of misunderstand-
ing or insufficient explanation.
Fourthly, the Bayesian formulation enables gradual results and
actionable probabilities to be obtained. Thus, constrained by the
small sample size, the evidence is limited for ALND or TNM stage III
tumors, although the model suggests that a possible negative
effect of these factors is highly probable. Depending on the
external context, clinicians must determine the degree to which
the differences in probability are clinically relevant in each case.
This makes the Bayesian approach an appealing, pragmatic
Fig. 2 Partial effects on log odds. Partial effect plots are shown with 0.95 highest posterior density intervals. Point estimates are posterior
modes. BCS breast-conserving surgery, M mastectomy, ALND axillary lymph node dissection, EORTC European Organisation for Research and
Treatment of Cancer, TNM tumor-node-metastases, ML medium-low, H high, VH very high. Note: the EORTC variable refers to the sum score.
Fig. 1 Box plots illustrating the quality-of-life domain scores. (A) quality-of-life domain scores pre-chemotherapy; (A) and after concluding
systemic adjuvant therapy (B). Note: The graph presents the median, the first and third quartile (25th and 75th percentiles), maximum scores,
and individual points that were outside the extremes of the whiskers. The hormonal status of the six males with breast cancer was coded as
unknown. BSC breast-conserving surgery, QoL quality of life, HE health status, PH physical domain, RO role domain, EF emotional functioning,
SO social domain, CO cognitive domain.
A. Carmona-Bayonas et al.
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method. In this line, Spiegelhalter et al. have proposed that the
post hoc Bayesian interpretation be routinely used in clinical trial
analyses26. The Bayesian CPPO model brings together the
requirements to meet this function in terms of interpreting
gradual QoL outcomes. Fifthly, in addition to causal inference,
the complete Bayesian model can be used for patient profile-based
predictions. Thus, the tool enables nomograms or online
calculators to be built, factoring in the aforementioned considera-
tions. This allows clinical questions to be answered, such as: What
is my probability of achieving a certain level of QoL according to
my specific characteristics? On the other hand, the bivariate
methods so assiduously applied, are unable to capture these
nuances, or do so only partially10.
The web calculator is potentially useful, and its relevance must
be put into context. BCS was developed more than 40 years ago as
an alternative to modified radical mastectomy (MRM) in T1-2
tumors27,28. Survival following BCS and radiotherapy is compar-
able to survival following MRM29,30, with better esthetic outcomes.
Over time, the indication of BCS was extended to T3 tumors or
tumors with node involvement (N+ ), after responding to
neoadjuvant chemotherapy27,31. Given that survival outcomes
with BCS and MRM are commensurate when BSC is indicated,
knowing the impact on mid-term QoL acquires special interest in
decision making4. Several studies have reported differences in
specific QoL domains related to type of surgery32–36. A recent
meta-analysis confirmed that BCS improved certain aspects of QoL
(e.g., body image, future perspectives, or treatment sequelae), but
not all of them10, requiring more prospective studies to elucidate
the impact37. After half a century of clinical research in this field, it
is striking that important aspects such as the modification of the
effect on QoL according to age, or individualized prediction, are
still seldom explored10.
Our study has various limitations. First of all, the specific EORTC
module for women with breast cancer, the QLQ-BR23, was not
administered38. The use of the global health status detects
generic changes and accounts for three quarters of the variability
of the complete score, but may be insensitive to certain aspects.
Secondly, QoL is a dynamic construct that varies based on time
since interventions. However, some trajectories are stable
according to individual clinical profile24. Here, the response
variable was the health status evaluated at the end of systemic
chemotherapy since this is the only post-baseline timepoint
contemplated. The QoL recorded prior to chemotherapy was
used as a covariate (baseline measurement taken as the starting
point). However, it is plausible that the progressive disappearance
of adverse effects would accentuate the differences between BCS
and mastectomy at a later stage of evolution (for instance, 2
years). Therefore, assessing QoL at several timepoints, over a
minimum of 1–2 years of follow-up might be more relevant. If
more measures were available, the CPPO model allows random
effects from longitudinal data to be integrated. Moreover, the
reader should be aware that baseline QoL scores were obtained
post surgery and may be worse than pre-surgery scores. As in
other studies, NEOCOPING has questionnaires that were not
completed at the 6-month timepoint. Nonetheless, the clinical
scenario is adjuvancy, and most are confirmed missing at random
and not due to clinical decline. In any case, the library makes it
possible to work with multiple imputations of these data, if
necessary22. Thirdly, other clinical elements that can affect QoL,
such as early breast reconstruction or radiotherapy, have not
been completed. These factors do indeed modulate QoL in some
Fig. 3 Odds ratios based on the CPPO model. HDI highest density interval, ALND axillary lymph node dissection, TNM tumor-node-
metastases, OR odds ratio. Note: odds ratios are based on posterior mode parameters, also displaying the 0.95 highest posterior density
intervals. The shades of blue represent different cutoffs of the response variable (health status at 6 months). The plot reveals the linear
constrained effect on the predictors. We can see that the CPPO model assumes proportional odds for all variables, except for baseline QoL and
age (that interacts with surgery). The model imposes a linear restriction on the coefficients of these variables that do not meet the
proportional odds assumption with respect to cutoffs. In contrast, the variables that do meet the proportional odds assumption have a single
odds ratio that is valid for the entire range of possible cutoffs.
A. Carmona-Bayonas et al.
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patients. Other uncommon variables or those not supported by
the model, such as level of education, occupation, marital status,
or specific comorbidities, might also be relevant for some
patients. Fourth, the model was causally specified to explore
the effect of surgery; consequently, the interpretation of the
remaining effect estimates, including ‘secondary exposures’ such
as perceived risk of recurrence, can be challenging39. Fifth, the
self-report subjective measures may have limitations, such as
response bias (social desirability, inaccurate memory, etc.) and
difficulty in fully comprehending the questionnaire. Finally, the
model must be independently and prospectively validated for its
clinical implementation.
Table 2. Odds ratios of the constrained partial proportional odds model.
Health status thresholds OR (95% HPDI) Posterior probability of harm (OR < 1)
EORTC QLQ-C30 sum score, 60 vs 85 ≥50 0.54 (0.27–1.12) 95%
≥66 0.34 (0.20–0.62) 100%
≥75 0.27 (0.15–0.47) 100%
≥83 0.21 (0.11–0.38) 100%
Perceived risk of recurrence, very high vs medium-low Any 0.47 (0.23–1.04) 97%
Perceived risk of recurrence, very high vs high Any 0.84 (0.49–1.46) 73%
Perceived risk of recurrence, high vs medium-low Any 0.56 (0.27–1.11) 56%
No ALND Any 0.77 (0.40–1.52) 79%
Age, 40 vs 55 years ≥50 0.26 (0.08–0.82) 99%
≥66 0.37 (0.15–0.92) 98%
≥75 0.45 (0.19–10.6) 97%
≥83 0.53 (0.21–1.28) 92%
TNM stage, 3 vs 2 Any 0.67 (0.27–1.68) 81%
TNM stage, 2 vs 1 Any 1.11 (0.63–2.01) 35%
Nontaxane regimen Any 1.04 (0.55–1.84) 44%
Mastectomy ≥50 0.30 (0.11–0.84) 99%
≥66 0.42 (0.20–0.91) 99%
≥75 0.49 (0.24–0.99) 98%
≥83 0.57 (0.28–1.23) 93%
We can see that the CPPO model assumes proportional odds for all variables, except for baseline QoL and age (that interacts with surgery). The model imposes
a linear restriction on the coefficients of these variables that do not meet the proportional odds assumption with respect to cutoffs. In contrast, the variables
that do meet the proportional odds assumption have a single odds ratio that is valid for the entire range of possible cutoffs. The EORTC QLQ-C30 sum score
was measured before adjuvant chemotherapy.
ALND axillary lymph node dissection, CI confidence interval, TNM tumor–node–metastases, OR odds ratio, HPDI highest posterior density interval.
Fig. 4 Example of global health status prediction for four patient profiles. The predictions with or in mastectomy in young or middle-aged
women are shown. HDI highest density interval.
A. Carmona-Bayonas et al.
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Bearing these limitations in mind, the conditions of applicability
must always be verified. Consequently, the conclusions are
generalizable to women who have undergone surgery for breast
cancer for whom adjuvant chemotherapy initiation is being
contemplated. Despite the fact that this limits the sphere of
application of the model and the gradual decrease in chemother-
apy notwithstanding thanks to predictive genomic tests, che-
motherapy continues to be part of many women’s experience of
cancer (e.g., luminal breast cancer in premenopausal or post-
menopausal women with positive nodes and high-risk negative
nodes, as well as in most triple-negative or HER2-positive
tumors)40. One could speculate that the differences between
mastectomy and BCS might be different in women without
chemotherapy, given that the impact of surgical sequelae and
changes in self-image would not have been diluted by the full
burden of post-chemotherapy side effects.
As for the generalizability of the method itself, the Bayesian
CPPO model comprises a new, extremely versatile, and flexible
tool to investigate QoL associated with cancer in multiple
scenarios, facilitating the obtention of rich, individualized descrip-
tions of patients’ evolution.
In short, we have fit a Bayesian ordinal model using software
programmed for COVID-19 trials to illustrate its usefulness in
analyzing QoL in oncological patients. The model makes it possible
to overcome certain issues associated with QoL analyses with
assumable complexity and accurately capture the main factors that
affect global health status (type of surgery, interaction with age, or
perceived risk of recurrence). The study demonstrates the feasibility
of post hoc Bayesian analysis with QoL data that can be
implemented in clinical trials. This Bayesian model is also a potentially
useful tool in making decisions grounded in the foreseeable
evolution of QoL, when facing therapies of comparable benefit.
METHODS
Patients and study design
The data are from a prospective cohort of individuals with early and locally
advanced breast cancer from the NEOCOPING multicohort study. This
study was promoted by the Continuous Care Group of the Spanish Society
of Medical Oncology (SEOM, for its acronym in Spanish) and was
conducted at 17 Spanish hospitals between 2016 and 2019 (Supplemen-
tary Table 1)41–45. The participating centers are tertiary university hospitals
distributed all over Spain. The participants had undergone surgery with
curative intent for nonadvanced cancers for which clinical guidelines
report adjuvant chemotherapy as a valid alternative. The study sought to
explore biopsychosocial and pathological aspects that affected the quality
of life, coping, and oncologist–patient communication.
For this analysis, women ≥18 years were chosen, with a histologically
confirmed diagnosis of breast cancer, stages TNM I–III, and indication of
adjuvant chemotherapy. All participants were recruited during the interval
between surgery and initiation of adjuvant chemotherapy. The patients
included were those who consulted with Medical Oncology and were
selected consecutively and prospectively by the medical oncologist.
Exclusion criteria included receiving neoadjuvant therapy and scheduled
to receive adjuvant hormone therapy alone or radiotherapy without
chemotherapy.
Ethical statement. This study was performed in accordance with the
ethical standards of the Declaration of Helsinki and its subsequent
amendments. This observational, noninterventional trial was approved by
the Research Ethics Committee of the Principality of Asturias (19 January
2015) and by the Spanish Agency of Medicines and Medical Devices
(AEMPS) (number: L34LM-MM2GH-Y925U-RJDHQ).
Informed consent statement. All subjects signed informed consent forms
and agreed to participate prior to completing baseline questionnaires.
Consent for publication. Informed consent and approval by the compe-
tent national authorities includes permission for publication and dis-
semination of the data.
Measures and variables
Participants completed the self-report European Organisation for Research
and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-
C30) scale46. This instrument can be downloaded in English and Spanish at
https://qol.eortc.org/. This questionnaire is a cancer-specific QOL instru-
ment, psychometrically validated for most tumors, and the most widely
used tool to quantify cancer patients’ QoL38,47,48. It is a 30-item, self-report
questionnaire that covers five QoL dimensions: physical (5 items), role (2),
emotional (4), social (2), and cognitive (2); an overall health status
assessment (2), and the following specific symptoms: pain (2), fatigue (3),
and nausea and vomiting (2 items). It contains six items to appraise
financial impact, as well as other symptoms (such as constipation, sleep
problems, hyporexia, etc.). The score is expressed on a scale of 0 to 100
(the higher the score, the better the QoL or more symptoms according to
the item)49 and takes less than 15min to complete50. The reliability of
these scales denotes suitable internal consistency (Cronbach’s alpha
≈0.67–0.92)51. The information from the questionnaire was agglutinated
into a sum score and evaluated in line with the scoring manual
recommended by the EORTC QoL Group49,52. The scale has been translated
and validated in Spanish53.
Since the questionnaire has items that are prima facie scantly applicable
to subjects with few symptoms (e.g., diarrhea, nausea, fatigue…), the
calculator uses the global health status (average of items 29 and 30) at
6 months as the response variable. Health status correlated closely to the
EORTC sum score (Spearman, ρ= 0.88) and accounted for 75% of its
variability by means of only two items: “How would you rate your overall
health during the past week?” and “How would you rate your overall
quality of life during the past week?”.
When selecting covariates, the limiting sample size was contemplated to
evaluate an ordinal response variable, as well as the need to nonlinearly
model some variables54. Taking into account the maximum number of
parameters the model can support, the covariates were selected after a
bibliographic review and at the researchers’ discretion. These predictors
were age (continuous, nonlinear), TNM classification of malignant tumors,
8th edition (stage I, II, III), patient’s perceived risk of recurrence (4-point
Likert scale: low/intermediate/high/very high risk), type of surgery on the
primary tumor (total mastectomy vs BCS), axillary surgery (axillary lymph
node dissection (ALND) [yes vs no]), the pre-chemotherapy EORTC QLQ-
C30 sum score, and planned chemotherapy regimen (taxane-containing
regimens and use of anthracyclines). Other clinical or sociodemographic
variables (e.g., social status, number of children, etc.) were considered for
descriptive purposes.
Procedures
The QoL evaluations were performed twice, once after the first
appointment with the oncologist, approximately 1 month following
surgery for the primary tumor and 1 week prior to initiating adjuvant
therapy, and again, during the month following completion of adjuvant
chemotherapy, some 6 months after initiation and prior to undertaking
adjuvant radiotherapy/endocrine therapy when necessary. Baseline ques-
tionnaires were completed by the participants themselves after their visit
to the oncologist, during which they were informed about the risk of
relapse and indication of adjuvant therapy.
Statistical analysis
The rmsb package enables Bayesian CPPO models to be fitted. Vague
priors (noninformative) were used here for coefficients. As the response
variable, the health status endpoint is an ordinal variable with 13 levels,
scaled from 0-100. The CPPO model determines the probability that the
participants would have a health status Y ≥ j, with j being each of the 13
levels. The PO assumption was assessed separately for each predictor
computing logits for each proportion of the form Y ≥ j, with j being the
thresholds for the ordinal response variable. When the PO is maintained,
the difference of logits between various j values should be similar for
different levels of the predictor54. Bearing this in mind, we fitted a CPPO
model as per the formulation proposed by Peterson & Harrell15. Here, this
model assumes PO for all variables, except for age and baseline EORTC
QLQ-C30 sum score. Nonlinear relations were assessed by means of
restricted cubic splines (age) or adding quadratic terms to the equation
(baseline EORTC QLQ-C30 summary score). Moreover, the model
contemplates the interaction between surgery and age. We run a Markov
chain Monte Carlo (MCMC) method with 4 chains, 2000 iterations, and a
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burn-in of 1000 samples, in each one. The c-index and the Brier score have
been used as measures of model performance. For comparison between
alternative models (e.g., with or without the covariate ‘anthracyclines’), we
used the widely applicable information criterion (WAIC) for parsimony55.
Odds ratios (OR) < 1 indicate worse QoL scores in the presence of a binary
variable. In the variables that deviate from the PO assumption, the model
imposes a linear restriction on the coefficients (e.g., the variable has a
different OR for each QoL score cutoff, but all of them are linearly related).
In contrast, those variables that do meet the proportional odds
assumption have a single odds ratio that is applicable to the entire range
of possible cutoffs. To illustrate these concepts, the prediction has been
visually depicted for the different levels, odds ratios, and partial effects,
and it has been contrasted with the evaluation of average effects stratified
for a single variable. The global health status predictive model was
depicted graphically by a web calculator programmed in .NET and R.
For comparative purposes, a frequentist PO model and a multinomial
model were also fitted. QoL scores according to type of surgery were also
compared by means of two-samples Wilcoxon tests (α= 0.05, two-tailed
tests).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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